Tennor Therapeutics wins China NMPA clearance for TNP-2092 phase IIb PJI trial

• Tennor Therapeutics received China NMPA clearance to launch a multicenter Phase IIb trial of TNP-2092 for prosthetic joint infections.
• The move follows positive Phase IIa interim data locked on July 1, 2026, showing 100% success in early or acute cases at 6 months.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tennor Therapeutics (Suzhou) Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260907-12322429), on September 07, 2026, and is solely responsible for the information contained therein.